Established in 2013, Rekah’s R&D division has labs with advanced equipment that enable it to develop and license new products.

Our three primary types of R&D projects are:

  • formulating generics
  • developing combination therapeutic entities
  • upgrading dossiers to eCTD format

Our R&D division focuses on two core areas:

  • unique tablets, mainly steroids
  • ophthalmic products

The group's R & D program includes accelerating the development and registration of corticosteroid preparations.

In March 2022, the Rekach Group inaugurated a new and advanced R&D center in Kfar Saba, Israel.